Affirmed Therapeutics BV (NASDAQ:AFMD) shot up 4.8% during mid-day trading on Friday . The stock traded as high as $2.89 and last traded at $2.85, with a volume of 52,414 shares traded. The stock had previously closed at $2.72.

Several brokerages have issued reports on AFMD. Leerink Swann began coverage on Affirmed Therapeutics BV in a report on Saturday, April 2nd. They issued a “buy” rating for the company. Jefferies Group reduced their price objective on Affirmed Therapeutics BV from $5.00 to $4.00 and set a “hold” rating for the company in a research report on Thursday, May 19th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Affirmed Therapeutics BV in a research report on Wednesday, May 18th. Finally, BMO Capital Markets assumed coverage on Affirmed Therapeutics BV in a research report on Monday, April 11th. They set an “outperform” rating and a $7.00 price objective for the company. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $9.46.

The company’s market capitalization is $96.46 million. The company’s 50-day moving average is $3.07 and its 200 day moving average is $3.72.

Affirmed Therapeutics BV (NASDAQ:AFMD) last announced its earnings results on Wednesday, May 18th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by $0.08. The business earned $1.90 million during the quarter, compared to analysts’ expectations of $1.88 million. The business’s quarterly revenue was down 24.0% compared to the same quarter last year. Equities analysts predict that Affirmed Therapeutics BV will post ($0.95) EPS for the current fiscal year.

A hedge fund recently raised its stake in Affirmed Therapeutics BV stock. Tekla Capital Management LLC raised its stake in Affirmed Therapeutics BV (NASDAQ:AFMD) by 29.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 294,213 shares of the biopharmaceutical company’s stock after buying an additional 66,130 shares during the period. Tekla Capital Management LLC owned 0.97% of Affirmed Therapeutics BV worth $2,095,000 at the end of the most recent quarter.

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.